KLRC1 and cancer: (74) leveraged NKG2A by demonstrating that administration of a peptide cancer vaccine in murine tumor models increased the expression on NKG2A on CD8+ TIL; however this elevated expression allowed for superior NKG2A blockade, thus improving therapeutic efficacy (74).